RESEARCH TRIANGLE PARK, N.C. - February 15, 2001 - In alignment with the current contract pharmaceutical organization (CPO) structure established in selected geographic regions, Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the following executive appointment in Latin America:
Jay Vigotov, vice president, Clinical Business Development, Latin America. Vigotov will be responsible for business management of Quintiles Brazil. He will be responsible for all commercialization activities in Latin America as well as the company's Africa Indian region. This newly created position is aligned with the company's ongoing establishment of a contract pharmaceutical organization (CPO) structure in geographic regions where Quintiles' development, commercialization and information services are managed within a single organization. Vigotov will report to Oppel Greeff, M.D., president, Quintiles, South Africa, India and Latin America.
Vigotov has over 30 years experience in the pharmaceutical and pharmaceutical service industries in sales, marketing, marketing research, advertising and operations. In 1992, he joined Quintiles as vice president of Marketing and in 1998, he assumed responsibilities for Quintiles Clinical Services in Latin America. Vigotov's background in Latin America and Brazil includes experience in education, government and the pharmaceutical industry.
Dennis Gillings, Ph.D., chairman and chief executive officer of Quintiles Transnational, said: "Taking an integrated approach to providing pharmaceutical services to our regions means we make better use of our resources. But more importantly, we can offer even better service to our customers, making Quintiles the most comprehensive contract clinical and commercial operation in the Southern Hemisphere."
Quintiles Transnational is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles employs a global workforce of 18,000 in 39 countries. Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information visit the company's Web site at www.quintiles.com.
Information in this press release contains "forward-looking statements" about Quintiles. These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, our ability to complete development and commercialization of new products, the cost and timing of bringing new products to market compared with revenues which may be generated by them, market acceptance, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, the ability to create data products from data licensed to us and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.